Linee guida Linee guida per la diagnosi e - Cardiologia interventistica

G Ital Cardiol Vol 8 Ottobre 2007
patients at high risk for cardiovascular events. Circulation
2002; 105: 1650-5.
268. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.
Effects of an angiotensin-converting-enzyme inhibitor,
ramipril, on cardiovascular events in high-risk patients. The
Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med 2000; 342: 145-53.
269. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani
L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C.
Cyclooxygenase-2 expression is induced during human
megakaryopoiesis and characterizes newly formed
platelets. Proc Natl Acad Sci USA 2002; 99: 7634-9.
270. Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di
Gregorio D, Bucciarelli T, Davi G, Cuccurullo F, Patrono C.
Oxidant stress and aspirin-insensitive thromboxane biosynthesis
in severe unstable angina. Circulation 2000; 102:
1007-13.
271. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ,
DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase
inhibitors and the antiplatelet effects of aspirin.
N Engl J Med 2001; 345: 1809-17.
272. Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens
CH, Gaziano JM. Inhibition of clinical benefits of
aspirin on first myocardial infarction by nonsteroidal antiinflammatory
drugs. Circulation 2003; 108: 1191-5.
273. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective
effect of aspirin. Lancet 2003; 361: 573-4.
274. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S,
Buch P, Friberg J, Schramm TK, Abildstrom SZ, Kober L,
Madsen M, Torp-Pedersen C. Risk of death or reinfarction
associated with the use of selective cyclooxygenase-2 inhibitors
and nonselective nonsteroidal antiinflammatory
drugs after acute myocardial infarction. Circulation 2006;
113: 2906-13.
275. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel:
a review of the evidence. J Am Coll Cardiol 2005; 45:
1157-64.
276. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke
B, Stellos K, May AE, Gawaz M. Low response to
clopidogrel is associated with cardiovascular outcome after
coronary stent implantation. Eur Heart J 2006; 27: 2420-5.
277. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel
for coronary stenting: response variability, drug resistance,
and the effect of pretreatment platelet reactivity. Circulation
2003; 107: 2908-13.
278. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R,
Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod
H. Clopidogrel resistance is associated with increased risk
of recurrent atherothrombotic events in patients with acute
myocardial infarction. Circulation 2004; 109: 3171-5.
279. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany
VL, Brennan D, Topol EJ. Lack of adverse clopidogrelatorvastatin
clinical interaction from secondary analysis of
a randomized, placebo controlled clopidogrel trial. Circulation
2003; 108: 921-4.
280. Lim MJ, Spencer FA, Gore JM, Dabbous OH, Agnelli G,
Kline-Rogers EM, Dibenedetto D, Eagle KA, Mehta RH.
Impact of combined pharmacologic treatment with clopidogrel
and a statin on outcomes of patients with non-ST-segment
elevation acute coronary syndromes: perspectives
from a large multinational registry. Eur Heart J 2005; 26:
1063-9.
281. van Hecken A, Depre M, Wynants K, Vanbilloen H, Verbruggen
A, Arnout J, Vanhove P, Cariou R, De Schepper PJ.
Effect of clopidogrel on naproxen-induced gastrointestinal
blood loss in healthy volunteers. Drug Metab Drug Interact
1998; 14: 193-205.
282. Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard
JL, Choussat R, Beygui F, Payot L, Vignolles N, Metz-
666
ger JP, Thomas D. Impact of prior use or recent withdrawal
of oral antiplatelet agents on acute coronary syndromes.
Circulation 2004; 110: 2361-7.
283. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED,
Magid DJ, Krumholz HM, Rumsfeld JS. Impact of medication
therapy discontinuation on mortality after myocardial
infarction. Arch Intern Med 2006; 166: 1842-7.
284. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B,
Pinto DS, Ho KK, Cohen DJ, Garcia LA, Cutlip DE, Carrozza
JP Jr. Stent thrombosis after successful sirolimuseluting
stent implantation. Circulation 2004; 109: 1930-2.
285. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE.
Catastrophic outcomes of noncardiac surgery soon after
coronary stenting. J Am Coll Cardiol 2000; 35: 1288-94.
286. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez
Granillo GA, Sonnenschein K, Regar E, McFadden EP,
Sianos G, van der Giessen WJ, de Jaegere PP, de Feyter P,
van Domburg RT, Serruys PW. Thirty-day incidence and
six-month clinical outcome of thrombotic stent occlusion
after bare-metal, sirolimus, or paclitaxel stent implantation.
J Am Coll Cardiol 2005; 45: 947-53.
287. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM,
Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino
M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E,
Colombo A. Incidence, predictors, and outcome of thrombosis
after successful implantation of drug-eluting stents.
JAMA 2005; 293: 2126-30.
288. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird
T, Suddath WO, Weissman NJ, Torguson R, Kent KM,
Pichard AD, Satler LF, Waksman R, Serruys PW. Late
thrombosis in drug-eluting coronary stents after discontinuation
of antiplatelet therapy. Lancet 2004; 364: 1519-21.
289. Wilson SH, Fasseas P, Orford JL, Lennon RJ, Horlocker T,
Charnoff NE, Melby S, Berger PB. Clinical outcome of patients
undergoing non-cardiac surgery in the two months
following coronary stenting. J Am Coll Cardiol 2003; 42:
234-40.
290. Albaladejo P, Marret E, Piriou V, Samama CM. Perioperative
management of antiplatelet agents in patients with
coronary stents: recommendations of a French Task Force.
Br J Anaesth 2006; 97: 580-2.
291. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart
PB, Moliterno DJ, O’Gara P, Whitlow P. Prevention of premature
discontinuation of dual antiplatelet therapy in patients
with coronary artery stents. A Science Advisory from
the American Heart Association, American College of Cardiology,
Society for Cardiovascular Angiography and Interventions,
American College of Surgeons, and American
Dental Association, with Representation from the American
College of Physicians. Circulation 2007; 115: 813-8.
292. Bertrand ME, LaBlanche JM, Tilmant PY, Thieuleux FA,
Delforge MR, Carre AG, Asseman P, Berzin B, Libersa C,
Laurent JM. Frequency of provoked coronary arterial spasm
in 1089 consecutive patients undergoing coronary arteriography.
Circulation 1982; 65: 1299-306.
293. TIMI IIIB Investigators. Effects of tissue plasminogen activator
and a comparison of early invasive and conservative
strategies in unstable angina and non-Q-wave myocardial
infarction. Results of the TIMI IIIB Trial. Thrombolysis in
Myocardial Ischemia. Circulation 1994; 89: 1545-56.
294. FRISC-II Investigators. Invasive compared with non-invasive
treatment in unstable coronary-artery disease: FRISC-II
prospective randomised multicentre study. FRagmin and
Fast Revascularisation during InStability in Coronary artery
disease Investigators. Lancet 1999; 354: 708-15.
295. Rioufol G, Gilard M, Finet G, Ginon I, Boschat J, Andre-
Fouet X. Evolution of spontaneous atherosclerotic plaque
rupture with medical therapy: long-term follow-up with intravascular
ultrasound. Circulation 2004; 110: 2875-80.